Cargando…
TIPS-22 A TWO-PART, PHASE 1 STUDY OF RHENIUM (186RE) OBISBEMEDA (186RNL) DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) FOR RECURRENT, REFRACTORY, OR PROGRESSIVE CHILDHOOD EPENDYMOMA AND HIGH-GRADE GLIOMA (HGG)
INTRODUCTION: Childhood ependymoma and HGG are difficult tumors to treat. Recurrent ependymoma is treated with re-resection and multiple rounds of EBRT. HGG is treated with chemoradiation followed by clinical trials, if available. While EBRT remains a central component of management, it is limited b...
Autores principales: | Plant, Ashley, DeCuypere, Michael, Lam, Sandi, Quijano, Carla, Bao, Ande, Moore, Melissa, LaFrance, Norman, Hedrick, Marc, Brenner, Andrew, Michalek, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402359/ http://dx.doi.org/10.1093/noajnl/vdad070.152 |
Ejemplares similares
-
TIPS-23 SAFETY AND FEASIBILITY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN RECURRENT GLIOMA: THE RESPECT-GBM TRIAL
por: Brenner, Andrew, et al.
Publicado: (2023) -
LMAP-21 PRELIMINARY CLINICAL DATA IN THE PHASE 1/2A DOSE ESCALATION TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN LEPTOMENINGEAL METASTASES (LM): THE RESPECT-LM TRIAL
por: Youssef, Michael, et al.
Publicado: (2023) -
EPCT-18. A TWO-PART, PHASE 1 STUDY OF RHENIUM-186 NANOLIPOSOME (186RNL) DELIVERED BY CONVECTION ENHANCED DELIVERY FOR RECURRENT, REFRACTORY, OR PROGRESSIVE EPENDYMOMA AND HIGH-GRADE GLIOMA (HGG) AND NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Plant, Ashley, et al.
Publicado: (2021) -
LOCL-04 SAFETY AND FEASIBILITY OF RHENIUM-186 NANOLIPOSOME (186RNL) IN LEPTOMENINGEAL METASTASES [LM] PHASE 1/2A DOSE ESCALATION TRIAL
por: Brenner, Andrew, et al.
Publicado: (2022) -
LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021)